TIGER'S TAKE: On our trading list, a promising but very volatile biotech stock. Today Citi analyst came out with a Buy rating and comments. We added our quick 4-month tech chart. $AMRN Now an attractive time to buy Amarin shares, says Citi Citi analyst Joel Beatty continues to believe Amarin's Vascepa will likely be granted a cardiovascular risk reduction label shortly after the FDA panel meeting scheduled for November. This makes now an attractive time to buy the stock, Beatty tells investors in a research note. During a recent fireside chat, Amarin CEO John Thero highlighted two major upcoming sales inflection points, says the analyst. The first is the promotion of an expanded CV risk reduction label and the second is direct-to-consumer marketing, which the company expects to be able to begin six months after a label expansion, Beatty points out. The analyst believes this is likely to be a "powerful tool for patent education and physician education." He keeps a Buy rating on Amarin.Source: (thefly.com) Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal. If you liked this article, please click the LIKE (thumbs up) button. Feel free to leave any comments, question, or opinions. (Sign-up if you haven't already done so). Follow us/bookmark us and check back occasionally for additional articles or comments on our page... Wild Tiger Trading - start/main page. * NOTE: As with all biotech stocks this is not without above average risk.... *